Evidence map›Paper›PMID 37176159›Full record

ArticleInternational journal of molecular sciences2023

Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics.

Konstantinos Kelaidonis, Irene Ligielli, Spiros Letsios, Veroniki P Vidali, Thomas Mavromoustakos, Niki Vassilaki, Graham J Moore, Weronika Hoffmann, Katarzyna Węgrzyn, Harry Ridgway and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Konstantinos KelaidonisNewDrug PC, Patras Science Park, 26504 Patras, Greece.
Irene LigielliDepartment of Chemistry, Laboratory of Organic Chemistry, National Kapodistrian University of Athens, 15772 Athens, Greece.
Spiros LetsiosNewDrug PC, Patras Science Park, 26504 Patras, Greece.
Veroniki P VidaliNatural Products and Bioorganic Chemistry Laboratory, Institute of Nanoscience & Nanotechnology, NCSR "Demokritos", 15341 Athens, Greece.ORCID 0000-0001-9020-8726
Thomas MavromoustakosDepartment of Chemistry, Laboratory of Organic Chemistry, National Kapodistrian University of Athens, 15772 Athens, Greece.ORCID 0000-0001-5309-992X
Niki VassilakiLaboratory of Molecular Virology, Hellenic Pasteur Institute, 11521 Athens, Greece.ORCID 0000-0001-7992-3438
Graham J MooreDepartment of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada.
Weronika HoffmannLaboratory of Virus Molecular Biology, Intercollegiate Faculty of Biotechnology of University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, Abrahama 58, 80-307 Gdansk, Poland.
Katarzyna WęgrzynLaboratory of Molecular Biology, Intercollegiate Faculty of Biotechnology of University of Gdańsk and Medical University of Gdańsk, University of Gdańsk, Abrahama 58, 80-307 Gdansk, Poland.ORCID 0000-0002-3743-8597
Harry RidgwayInstitute for Sustainable Industries and Liveable Cities, Victoria University, Melbourne, VIC 8001, Australia.
Christos T ChasapisInstitute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.ORCID 0000-0002-8728-6245
John M MatsoukasNewDrug PC, Patras Science Park, 26504 Patras, Greece.ORCID 0000-0001-5554-2964
Gdańsk Medical University · PLNational and Kapodistrian University of Athens · GRUniversity of Calgary · CANational Centre of Scientific Research "Demokritos" · GRNational Hellenic Research Foundation · GRPasteur Hellenic Institute · GRVictoria University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study is an extension of current research into a novel class of synthetic antihypertensive drugs referred to as "bisartans", which are bis-alkylated imidazole derivatives bearing two symmetric anionic biphenyltetrazoles. Research to date indicates that bisartans are superior to commercially available hypertension drugs, since the former undergo stronger docking to angiotensin-converting enzyme 2 (ACE2). ACE2 is the key receptor involved in SARS-CoV-2 entry, thus initiating COVID-19 infection and in regulating levels of vasoactive peptides such as angiotensin II and beneficial heptapeptides A(1-7) and Alamandine in the renin-angiotensin system (RAS). In previous studies using in vivo rabbit-iliac arterial models, we showed that Na

Indexed as

COVID-19Angiotensin-Converting Enzyme 2Angiotensin II Type 1 Receptor BlockersAnimalsAntihypertensive AgentsBinding SitesHumansProtein BindingRabbitsSARS-CoV-2Angiotensin-Converting Enzyme 2Angiotensin II Type 1 Receptor BlockersAntihypertensive AgentsACE2bisartansCOVID-19RASRBDSARS-CoV-2tetrazole

Identifiers

PMID37176159
PMCPMC10179460
OpenAlexW4376630017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.